secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005446
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport accelerates Phase 3 start for RAP-219 in focal seizures to Q2 2026; expands epilepsy portfolio into PGTCS
--------------------------------------------------------------------------------

- Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.
- New epilepsy program in primary generalized tonic-clonic seizures (PGTCS); Phase 3 trial planned H1 2027.
- FDA removed clinical hold on DPNP IND; Rapport defers further DPNP investment to prioritize α6β4 program.
- $513M cash, cash equivalents and short-term investments as of Q3 2025; expected to fund operations into H2 2029.
- Phase 2 bipolar mania trial on track for H1 2027 topline; long-acting injectable IND-enabling activities start Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526005446/0001193125-26-005446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526005446/rapp-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer